CYP3A4*22 Genotype-Guided Dosing of Kinase Inhibitors in Cancer Patients

ConclusionNon-inferiority could not be proven for dose reduction of KIs metabolized by CYP3A4 inCYP3A4*22 carriers compared to the registered dose in wildtype patients. Therefore, an up-front dose reduction based upon theCYP3A4*22 SNP for all KIs does not seem an eligible new way of personalized therapy.Trial RegistrationInternational Clinical Trials Registry Platform Search Portal; number NL7514; registered 11/02/2019.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research